|
|
|
|
Characterization of CEM-101 Activity Against Gram-Positive Organisms [Article]
In vitro activity of CEM-101, a new fluoroketolide, was determined against Gram-positive organisms with various macrolide susceptibility profiles.Experiments for determination of MIC and MBC, timed-killing, single-step and multistep mutation rates, ...
|
|
|
Enhancement of Biofilm Formation by Subinhibitory Macrolides in icaADBC-Positive and -Negative Clinical Isolates of Staphylococcus epidermidis [Article]
Biofilm formation in Staphylococcus epidermidis is mediated by icaADBC -dependent and -independent pathways.Subinhibitory erythromycin, azithromycin and clarithromycin markedly enhanced, in vitro in a dose-dependent manner, biofilm formation of 20% (21...
|
|
|
Antibiotic Sensitivity Profiles Determined with an Escherichia coli Gene Knockout Collection: Generating an An
Antimicrobial Agents and Chemotherapy, April 2010, p.1393-1403, Vol. 54, No. 4 Copyright 2010, American Society for Microbiology. All Rights Reserved. , Anne Liu, Lillian Tran, Elinne Becket, Kim Lee, Laney Chinn, Eunice Park, Katherine Tran, and...
|
|
|
CEM-101, a novel fluoroketolide: antimicrobial activity against a diverse collection of Gram-positive and Gram
Shannon D.Putnama, b, , , Mariana Castanheiraa, Gary J. Moeta, David J. Farrella and Ronald N. Jonesa, c a JMI Laboratories, North Liberty, IA 52317, USA b Epidemiology Department, College of Public Health, University of Iowa, Iowa City, IA 52240, USA...
DiagnosticMicrobiology and Infectious Disease:
Mar 18 2010 7:28PM
Matching: erythromycin
|
Find similar documents
|
|
|
|
Enhancement of Biofilm Formation by Subinhibitory Macrolides in icaADBC-Positive and -Negative Clinical Isolat
Antimicrob.Agents Chemother. doi:10.1128/AAC.01565-09 Copyright (c) 2010, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved. Qian Wang, Feng-Jun Sun, Yao Liu, Li-Rong Xiong, Lin-Li Xie, and Pei-Yuan Xia*...
|
|
|
Shruthi Bulk Drugs of Secunderabad booked for exporting ketamine without drug license
The Drugs Control Administration in Andhra Pradesh has registered a case under Section 18 (c) of Drugs and Cosmetics Act, 1940, against the Secunderabad-based Shruthi Bulk Drugs Pvt Ltd for purchasing, selling and exporting 3300 kg of Ketamine Hydrochloride US...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
ALAMEDA, Calif.-- (BUSINESS WIRE) -- (OTCBB: INSV) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by InSite Vision in which we executed against our strategic objectives,...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
AzaSite Revenues Up 91 Percent Over 2008 ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV - News) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV.OB) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by InSite Vision in which we executed against...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
(BUSINESS WIRE) ----InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the full year and fourth quarter ended December 31, 2009."2009 was a year of steady performance by InSite Vision in which we executed against our strategic...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
"2009 was a year of steady performance by InSite Vision in which we executed against our strategic objectives," said Louis Drapeau, InSite Vision's Chief Executive Officer."We begin 2010 in a solid cash position, having successfully conserved our financial...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
ALAMEDA, Calif.- (Business Wire) InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the full year and fourth quarter ended December 31, 2009. 2009 was a year of steady performance by InSite Vision in which we executed against our...
|
|
|
InSite Vision Reports Full Year and Fourth Quarter 2009 Financial Results
InSite Vision Incorporated (OTCBB: INSV) today reported financial results for the full year and fourth quarter ended December 31, 2009.2009 was a year of steady performance by InSite Vision in which we executed against our strategic objectives, said Louis...
|
|
|
Stater Bros. Super Rx Pharmacy Free Antibiotic Program Well Received
SAN BERNARDINO, Calif., March 5 /PRNewswire/ -- In September 2009, all 28 conveniently located Stater Bros.Super Rx Pharmacies throughout Southern California began offering a free 14-day supply of selected antibiotics, including refills, to anyone with or...
|
|
|
Inspire posts fourth-quarter net loss
Submit a Comment DURHAM, N.C.- Inspire Pharmaceuticals reported a net loss of $2.6 million, or $0.03 per share, for the fourth quarter of 2009 and a net loss of $40 million, or $0.60 per share, for the full year, according to a press release from the company...
|
|
|
Stater Bros. Super Rx Pharmacy Free Antibiotic Program Well Received
Thousands of FREE ANTIBIOTIC prescriptions have been filled to ensure accessibility to affordable health care SAN BERNARDINO, Calif., March 5 /PRNewswire/ -- In September 2009, all 28 conveniently located Stater Bros.Super Rx Pharmacies throughout Southern...
|
|
|
Stater Bros. Super Rx Pharmacy Free Antibiotic Program Well Received
Companies mentioned in this article: Stater Bros.Holdings Inc. SAN BERNARDINO, Calif., March 5 /PRNewswire/ -- In September 2009, all 28 conveniently located Stater Bros. Super Rx Pharmacies throughout Southern California began offering a free 14-day...
|
|
|
Top 10 destination countries of Erythromycin Thiocyanate in 2009
_ Top 10 destination countries of Erythromycin Thiocyanate in 2009.
|
|
|
Inspire Pharma Q4 Loss Narrows Significantly - Update
3/4/2010 9:23 AM ET RELATED NEWS Trade ISPH now with TOP MARKET NEWS (RTTNews) - Inspire Pharmaceuticals, Inc.(ISPH: News ), Thursday, reported a sharply narrower loss for the fourth quarter, reflecting a 57% increase in revenue driven by strong growth in...
|
|
|
Inspire Pharma says 4th quarter narrowed due to boost in Azasite solution sales
DURHAM, N.C.(AP) Inspire Pharmaceuticals Inc. said Thursday it had a smaller loss in the fourth quarter, as sales of its pinkeye treatment Azasite climbed due to a shortage of a competing product. Inspire said Azasite solution sales rose 67 percent to ...
|
|
|
Inspire posts smaller loss as Azasite sales rise
Inspire Pharmaceuticals Inc.said Thursday it had a smaller loss in the fourth quarter, as sales of its pinkeye treatment Azasite climbed due to a shortage of a competing product. Inspire said Azasite solution sales rose 67 percent to $12.1 million as a...
|
|
|
Inspire Pharma says 4th quarter narrowed due to boost in Azasite solution sales
DURHAM, N.C.Inspire Pharmaceuticals Inc. said Thursday it had a smaller loss in the fourth quarter, as sales of its pinkeye treatment Azasite climbed due to a shortage of a competing product. Inspire said Azasite solution sales rose 67 percent to $12.1...
|
|
|
Inspire Reports Fourth Quarter and Full Year 2009 Financial Results
DURHAM, N.C.-- (BUSINESS WIRE) --.(NASDAQ: ISPH) announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or (...
|
|
|
Inspire Pharmaceuticals reports net loss of $2.6 million for 2009 fourth quarter
Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today financial results for the fourth quarter and year ended December 31, 2009, reporting a net loss of $2.6 million or ($0.03) per share for the fourth quarter and a net loss of $40.0 million or ($0.60)...
|
|
|
Inspire Reports Fourth Quarter and Full Year 2009 Financial Results
- Fourth Quarter Revenue Increased 57% and Net Loss Decreased 74% - - Full Year Revenue Increased 31% and Net Loss Decreased 23% - DURHAM, N.C.--(BUSINESS WIRE)--Mar 4, 2010 - Inspire Pharmaceuticals, Inc.(NASDAQ: ISPH) announced today financial results for...
|
